Entera Bio To Present At The H.C. Wainwright Global Life Sciences Conference
Entera Bio Ltd. (NASDAQ: ENTX) announced participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) announced participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Spiros Jamas will present an overview of the company’s business during this virtual event. A webcast of the presentation will be available on Entera's website starting March 9 at 7 a.m. ET. Entera is focused on developing orally delivered large molecule therapeutics, with key products like EB613 and EB612 in Phase 2 clinical development.
Details
News Market Reaction – ENTX
The recorded move for ENTX in the trading session of this news was -11.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate in the H.C. Wainwright Global Life Sciences Conference. As part of the virtual conference, which is being held March 9-10, 2021, Spiros Jamas, Entera’s Chief Executive Officer will present an overview of the Company's business.
A webcast of the presentation will be available starting on March 9 at 7 a.m. ET and can be accessed on the “Investor Relations” page of Entera’s website, by clicking here.
About Entera Bio
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.